Pharma and Healthcare Newsletter - July 10 to July 14, 2017

India Infoline News Service | Mumbai | July 15, 2017 09:57 IST

This week, “Mylan N.V. and Biocon on Friday announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies’ proposed biosimilar trastuzumab.”

Medical supplies, pills and capsules
Top news
 
USFDA’s ODAC recommends approval of Mylan and Biocon’s proposed Biosimilar Trastuzumab

Mylan N.V. and Biocon on Friday announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies’ proposed biosimilar trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin, which include HER2-positive breast cancer in the metastatic and adjuvant settings. Read More

Zydus gets final approval from USFDA for Memantine Hydrochloride tablets

Zydus Cadila, in a BSE filing on Wednesday, said that the company has received the final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5 mg and 10 mg.

The drug is used for the treatment of moderate to severe dementia (Alzheimer’s type) and will be produced at the group’s facility in Moraiya, Ahmedabad. Read More

Piramal to expand overseas pharma biz

Mumbai-headquartered, Piramal Enterprises has plans to introduce more products going forward and it is looking to expand the presence of its pharma vertical in strong global markets such as the US, Europe and Japan.

Europe and North America contribute over 70% of the company's revenue from pharmaceuticals business. Read More

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.